Look­ing to ce­ment its lead in packed MS mar­ket, Roche's Ocre­vus un­corks new da­ta in ear­ly-stage pa­tients

Among a pos­i­tive­ly jam-packed mul­ti­ple scle­ro­sis mar­ket, Roche’s Ocre­vus has man­aged to stand out for what the Swiss drug­mak­er is call­ing the most suc­cess­ful launch in its long his­to­ry. But in or­der to press its ad­van­tage, Ocre­vus is look­ing to ear­li­er-stage pa­tients, and new in­ter­im da­ta should help build its case there.

Af­ter 48 weeks on Roche’s Ocre­vus, 85% of new­ly di­ag­nosed pri­ma­ry pro­gress­ing or re­laps­ing MS pa­tients with­out a his­to­ry of dis­ease mod­i­fy­ing ther­a­py post­ed no dis­ease ac­tiv­i­ty, in­clud­ing dis­ease pro­gres­sion or re­lapse, ac­cord­ing to in­ter­im da­ta set to be pre­sent­ed this week­end at the vir­tu­al Amer­i­can Acad­e­my of Neu­rol­o­gy meet­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER